| 000 | 03881nam a22003615i 4500 | ||
|---|---|---|---|
| 001 | 82385 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230207040409.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 150527s2015 gw | s |||| 0|eng d | ||
| 020 | _a9783319174679 | ||
| 024 | 7 |
_a10.1007/978-3-319-17467-9 _2doi |
|
| 050 | 4 |
_aRC280.T4 _b2015 EB |
|
| 245 | 1 | 0 |
_aDiagnosis and Management of Testicular Cancer : _bThe European Point of View _cedited by Susanne Krege. |
| 260 |
_aCham, Switzerland _bSpringer _c2015 |
||
| 300 |
_a1 recurso en línea (VIII, 135 páginas) _b9 ilustraciones en color |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 505 | 0 | _aPart I: Overview of the latest recommendations of the European Germ Cell CancerÂ{u7CAF}oup -- Part II: Special topics about controversial aspects, new results from studies, which might change treatment recommendations and long-term-survivorship: Is there still an indication for radiotherapy in seminoma CS I/ IIA/B?- How should we treat nonseminoma CSI? -- Is there still an indication for diagnostic RPLND in nonseminoma CSI? -- How could the prognosis of patients with intermediate risk disease be improved? -- How should patients with poor-prognosis disease be treated actually? -- How should patients with recurrent disease be treated actually? -- How important are prognostic factors for determining treatment in patients with primary or recurrent disease? -- What should be the boundaries in retroperitoneal residual tumor resection in nonseminoma? -- How should residual disease outside the retroperitoneum be treated? -- What are the recent recommendations for follow up in testicular cancer? -- What are the long-term toxicities to be controlled and treated? -- Consequences of the disease and its treatment concerning sexuality and fertility. | |
| 520 | 3 | _aThis book presents the views of leading European experts on the diagnosis and management of testicular cancer, with coverage of current hot topics in the field. It opens by providing an overview of the recommendations in the most recent consensus paper from the European Germ Cell Cancer Consensus Group, which is based on interdisciplinary cooperation among urologists, medical oncologists, radio-oncologists, pathologists, and basic scientists. The remainder of the book focuses on areas of controversy in the diagnosis, treatment, and follow-up of testicular cancer. In each case the evidence base is discussed and results from the most recent studies are reviewed, drawing attention to new findings that might alter treatment recommendations. The treatment-related chapters cover a broad range of issues, including the best approach in patients with poor-prognosis and recurrent disease and those with long-term toxicities. Relevant aspects of survivorship care are also addressed. The book will help clinicians and practitioners to achieve the goals of minimizing therapy and its side-effects without reducing efficacy in low stage disease, improving the cure rate in advanced disease, and enhancing follow-up and long-term survivorship. | |
| 710 | 2 |
_aSpringerLink (Online service) _0Local _9106996 |
|
| 942 |
_2lcc _cLE |
||
| 650 | 7 |
_aRadioterapia _2embne _9139979 |
|
| 650 | 7 |
_aUrología _2embne _9138565 |
|
| 650 | 2 | 7 |
_aUrología _2embne _9138565 |
| 700 | 1 |
_aKrege, Susanne _eeditor literario _995287 _0Local |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-17467-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 907 |
_a.b12910259 _b10-10-17 _c10-02-16 |
||
| 988 | _aSpringer_Medicine_2015 | ||
| 998 |
_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0 |
||
| 945 |
_aRC280.T4 D534 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11577939 _z06-04-17 |
||
| 999 |
_c82385 _d82385 _x1 |
||